Study of duvakitug for moderate to severe ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 to 80 years old
- You have had moderate to severe ulcerative colitis for at least 3 months
- Standard treatments (like mesalamine, steroids, or biologics) haven't worked or caused side effects
- You do not have Crohn's disease or other types of inflammatory bowel disease
- You have not had bowel surgery in the last 3 months or more than 3 bowel surgeries
- You are on stable doses of your current UC medications or not taking certain other medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This study tests whether adding a special turmeric supplement (CurQD) to the standard treatment vedolizumab helps calm moderate-to-severe ulcerative colitis more than vedolizumab alone. It may be a good option if your colitis is active despite current medications.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.